Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06274164 · ClinicalTrials.gov registry record
Clinical and Molecular Biomarker Studies in RAI1 (Retinoic Acid-Induced 1) -Related Disorders
A clinical trial of RAI1 Gene 17P11.2 Deletion+Duplication, sponsored by Baylor College of Medicine.
- Recruiting
- Registry status
- 90
- Enrollment target
- 1
- Study location
NCT06274164: Recruiting study of RAI1 Gene 17P11.2 Deletion+Duplication, sponsored by Baylor College of Medicine.
NCT06274164 is a study of RAI1 Gene 17P11.2 Deletion+Duplication that is actively recruiting participants, run by Baylor College of Medicine. The registered enrollment target is 90 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06274164, a study of RAI1 Gene 17P11.2 Deletion+Duplication, is actively recruiting participants, sponsored by Baylor College of Medicine.
- RECRUITING
- Registry status
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
Currently, there is no clinically available genetic-based treatment for RAI1 (Retinoic Acid-Induced 1) -related disorders other than symptomatic management and there are no established clinical or molecular biomarkers that could be used as measures for the efficacy of therapy in future treatment studies. Biomarkers are measures of what is happening inside the body, shown by the results of laboratory, imaging or other tests. Biomarkers can help doctors and scientists diagnose diseases and health conditions, monitor responses to treatment and see how a person's disease or health condition changes over time. The goal of this observational and laboratory study is to develop clinical, neurophysiology and molecular biomarkers in RAI1-related disorders. The main question\[s\] it aims to answer are: * to characterize the disease features more precisely and analyze the differentiating and overlapping features of RAI1-related disorders (Smith-Magenis syndrome and Potocki-Lupski Syndrome) * to identify clinical, neurophysiology, and laboratory biomarkers that differentiate RAI1-related disorders one from another. Participants will have to complete: * a clinical examination * a blood draw * a skin biopsy (optional) * a sleep study Researchers will compare patients' blood to control group's blood for biomarker studies.
Primary Outcome
Identify biomarkers which have suitable stability for use in clinical settings by combining quantitative comparisons from the visit with qualitative literature/retrospective chart review synthesis, to prioritize measures for inclusion in a panel of candidate biomarkers. Investigators expect to find a clinical exam finding such as tremor which can be measurable objectively or behavior which can be relied on caregiver's report.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Blood draw
- DIAGNOSTIC_TEST Electroencephalography/Polysomnography (EEG/PSG)
- PROCEDURE Skin Biopsy
Study Locations (1)
Texas
- Texas Children's Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-03-13 |
| Est. Completion | 2027-03 |
What NCT06274164 shows while recruiting
NCT06274164 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 90 participants, a relatively small participant target.
The record links to 1 condition, with RAI1 Gene 17P11.2 Deletion+Duplication appearing as the primary indexed condition, and to 3 interventions - of which Blood draw is the first listed.
NCT06274164 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06274164 about?
NCT06274164 is a clinical study titled "Clinical and Molecular Biomarker Studies in RAI1 (Retinoic Acid-Induced 1) -Related Disorders". Currently, there is no clinically available genetic-based treatment for RAI1 (Retinoic Acid-Induced 1) -related disorders other than symptomatic management and there are no established clinical or molecular biomarkers that could be used as measures for the efficacy of therapy in future treatment stu...
What is the current status of trial NCT06274164?
This trial is currently recruiting. The enrollment target is 90 participants. The study started on 2024-03-13. Estimated completion is 2027-03.
What conditions does trial NCT06274164 study?
This clinical trial studies the following conditions: RAI1 Gene 17P11.2 Deletion+Duplication.
What interventions are being tested in trial NCT06274164?
The interventions under investigation include: Blood draw (DIAGNOSTIC_TEST), Electroencephalography/Polysomnography (EEG/PSG) (DIAGNOSTIC_TEST), Skin Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT06274164?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06274164 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI